CN-105

Identification

Generic Name
CN-105
DrugBank Accession Number
DB18345
Background

CN-105 is a neuroprotective pentapeptide with the sequence Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 713.846
Monoisotopic: 713.440889171
Chemical Formula
C28H55N15O7
Synonyms
  • Ac-VSRRR- NH2
External IDs
  • CN 105
  • CN-105
  • CN105

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
W525NLS74J
CAS number
1632243-07-2
InChI Key
ZPSIKZCGZCSUNF-HVTWWXFQSA-N
InChI
InChI=1S/C28H55N15O7/c1-14(2)20(39-15(3)45)25(50)43-19(13-44)24(49)42-18(9-6-12-38-28(34)35)23(48)41-17(8-5-11-37-27(32)33)22(47)40-16(21(29)46)7-4-10-36-26(30)31/h14,16-20,44H,4-13H2,1-3H3,(H2,29,46)(H,39,45)(H,40,47)(H,41,48)(H,42,49)(H,43,50)(H4,30,31,36)(H4,32,33,37)(H4,34,35,38)/t16-,17-,18-,19-,20-/m0/s1
IUPAC Name
(2S)-5-carbamimidamido-2-[(2S)-5-carbamimidamido-2-[(2S)-5-carbamimidamido-2-[(2S)-2-[(2S)-2-acetamido-3-methylbutanamido]-3-hydroxypropanamido]pentanamido]pentanamido]pentanamide
SMILES
CC(C)[C@H](NC(C)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionPOCD - Postoperative Cognitive Dysfunction / Postoperative Delirium (POD)1
2CompletedSupportive CareCerebral Hemorrhage1
2CompletedTreatmentCerebral Hemorrhage1
2RecruitingTreatmentCerebral Hemorrhage1
1CompletedTreatmentCerebral Hemorrhage1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-6.6Chemaxon
pKa (Strongest Basic)12.43Chemaxon
Physiological Charge3Chemaxon
Hydrogen Acceptor Count16Chemaxon
Hydrogen Donor Count16Chemaxon
Polar Surface Area394.52 Å2Chemaxon
Rotatable Bond Count24Chemaxon
Refractivity211.77 m3·mol-1Chemaxon
Polarizability72.96 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at September 19, 2023 17:19 / Updated at September 21, 2023 13:10